inflammatory breast cancer cell
Recently Published Documents


TOTAL DOCUMENTS

26
(FIVE YEARS 3)

H-INDEX

4
(FIVE YEARS 0)

Cancers ◽  
2021 ◽  
Vol 13 (19) ◽  
pp. 4967
Author(s):  
Sara Caceres ◽  
Beatriz Monsalve ◽  
Angela Alonso-Diez ◽  
Belén Crespo ◽  
Maria Jose Illera ◽  
...  

Blocking estrogen synthesis by inhibitors of estrogen synthesis is a widely used therapy against estrogen receptor-positive tumors. However, these therapies are less effective in negative expression tumors. Therefore, this study determined the effectiveness of anti-aromatase and anti-sulfatase therapies in canine and human inflammatory breast cancer. Cell cultures and xenografts from IPC-366 and SUM149 were treated with different doses of letrozole (anti-aromatase) and STX-64 (anti-sulfatase), in order to observe their effectiveness in terms of cell proliferation, tumor progression, and the appearance of metastases and hormonal profiles. The results revealed that both treatments are effective in vitro since they reduce cell proliferation and decrease the secreted estrogen levels. In xenograft mice, while treatment with letrozole reduces tumor progression by 30–40%, STX-64 increases tumor progression by 20%. The hormonal results obtained determined that STX-64 produced an increase in circulating and intratumoral levels of estradiol, which led to an increase in tumor progression. However, letrozole was able to block estrogen synthesis by decreasing the levels of circulating and intratumoral estrogen and thus slowing down tumor progression. In conclusion, letrozole can be an effective treatment for canine and human inflammatory breast cancer. The knowledge of the hormonal profile of breast tumors reflects useful information on the effectiveness of different endocrine treatments.


2021 ◽  
Vol 8 (9) ◽  
pp. 194
Author(s):  
Sara Caceres ◽  
Angela Alonso-Diez ◽  
Belén Crespo ◽  
Laura Peña ◽  
Maria J. Illera ◽  
...  

Xenografts can grow in immunosuppressed hosts, such as SCID mice, and tumor material can be injected into hosts either ectopically or orthotopically. Choosing the correct model to use is a crucial step in animal research. The aim of this study was to report the differences between ectopic and orthotopic xenografts in tumor progression, metastasis capacity, histological features, and steroid hormone profiles in xenografts from the cIMC (canine inflammatory mammary cancer) cell line IPC-366 and hIBC (human inflammatory breast cancer) cell line SUM149. To achieve this purpose, 40 female mice 6–8 weeks old were inoculated with IPC-366 and SUM149 cells subcutaneously (ectopic models) or into mammary fat pad (orthotopic models). Mice were monitored for tumor progression and appearance of metastases, and generated tumors were analyzed in terms of histological examination and steroid hormone production. The results revealed differences in tumor appearance and percentage of metastasis between ectopic and orthotopic models, which were higher in the ectopic xenografts from both cell lines. However, both models had similar characteristics of tumor progression, histological features, and steroid hormone secretion profiles. We show that the ectopic model can be validated as a good and useful model of tumor development in addition to, not contrary to, the orthotopic model in breast cancer research.


2017 ◽  
Vol 118 (5) ◽  
pp. 1273-1273 ◽  
Author(s):  
Madhura Joglekar ◽  
Weam O. Elbazanti ◽  
Matthew D. Weitzman ◽  
Heather L. Lehman ◽  
Kenneth L. van Golen

Sign in / Sign up

Export Citation Format

Share Document